StockNews.AI
TMDX
StockNews.AI
209 days

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating TransMedics Group, Ltd. for potential violations of securities laws

1. Wolf Haldenstein is investigating claims of securities fraud against TMDX. 2. Scorpion Capital's report accused TMDX of fraud and organ trafficking. 3. TMDX shares dropped 5.15% after the fraud allegations were published. 4. A further decline of 6.9% occurred after ongoing concerns over fraud. 5. The investigation may influence investor confidence and TMDX's market performance.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Allegations of fraud can severely damage investor trust, leading to stock declines. Past examples include major healthcare companies facing similar accusations, resulting in significant stock drops.

How important is it?

The allegations and investigation into TMDX are highly relevant, potentially affecting its stock price. Investor reactions to legal scrutiny often impact valuation significantly.

Why Short Term?

Immediate reactions to fraud allegations typically affect stock prices quickly. Similar past cases show stock recovery can take time, but initial impacts are swift.

Related Companies

TMDXSCOR
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Ltd. (NASDAQ: TMDX) (“TransMedics” or the “Company”). The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud. PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. On January 10, 2025, Scorpion Capital issued a report about the Company alleging fraud, organ trafficking, and off-label device misuse. It stated that in “20 years of shorting, TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients - the terminally ill, desperate for an organ. The ‘lucky' patients who receive a diseased, damaged organ rejected by reputable surgeons and centers [. . .] are oblivious to the cesspool of perverse, secret incentives that steered the organ their way. [Corruption pervades] every aspect of the business model.” Following this news, TransMedics stock dropped $3.74 per share, or 5.15%, to close at $68.81 on January 10, 2025. On January 13, 2025, TransMedics stock dropped another $4.76 per share, or 6.9%, to close at $64.05. Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation. If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com. Contact: Wolf Haldenstein Adler Freeman & Herz LLPGregory Stone, Director of Case and Financial AnalysisEmail: gstone@whafh.com or classmember@whafh.comTel: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Related News